bluuebunny/crossref_metadata_2025_split huggingface dataset:
887-P: The impact of GABAA Positive Allosteric Modulator as Novel First-in-Class Approach for MASH Therapy
Authors: ROHBECK ELISABETH , KOESTER LEONIE , ECKEL JÜRGEN 
Published: June 2024

Introduction & Objective: Chronic liver injury represents a pathological wound-healing process. However, there is no approved pharmacological therapy for liver fibrosis. Since GABAergic signaling has been suggested to play a beneficial role in cytotoxic liver injury, we aimed to investigate if the hepatoprotective positive allosteric modulator of the GABAA receptor, HK3, could also ameliorate fibrosis in a human 3D spheroid MASH model. Moreover, AI- and chemoinformatic-based next-generation GABAA modulators will be in our focus as MASH therapeutics.
Methods: Cryopreserved primary hepatocytes and non-parenchymal cells from MASH patients were clustered to spheroids and supplemented with 10 μg/ml insulin (control group) or 10 mg/ml insulin and 240 μM palmitic acid (PA)/ oleic acid (OA) (MASH group) at HepaPredict. The CellTiter-Glo Luminescent Assay kit was used to assess viability for up to two weeks with repeated exposure of HK3. Subsequently, the effects of HK3 (1, 3, and 10 µM) for 1 week on intracellular lipid content were quantified using AdipoRed Assay. Secreted cytokines (IL-6, IL-8) or pro-Collagen type 1α1 were measured in the supernatants using Magnetic Luminex Assay or ELISA. The discovery of new hits was performed through generative AI molecule design and virtual screening with AI and docking simulations.
Results: Acute exposure to HK3 did not result in hepatotoxicity at any concentration. HK3 reduced hepatic lipid content (48%, 46%, and 49%) or pro-COL1A1 levels (82%, 73%, and 64%) compared to MASH, respectively. Exposure to 3 µM HK3 led to a strong decrease in IL-6 (55%) and IL-8 (80%) secretion. Iterative, AI-based identification of new hits and their in-depth functional analysis will be presented.
Conclusion: Our thioacrylamide compound promotes the regression of hepatic fibrosis, besides reducing steatosis and inflammation in a human 3D spheroid system. Overall, GABAA receptor modulators represent a first-in-class approach for MASH therapy.

Disclosure
E. Rohbeck: None. L. Koester: None. J. Eckel: None.
894-P: Safety and Efficacy of Imeglimin in Patients with Metformin Intolerance—Prospective Observational Study
Authors: AGRAWAL PRABHAT K. , GAUTAM ASHISH , PURSNANI NIKHIL , YADAV ALKA 
Published: June 2024

Introduction and Objectives: Metformin is the first line drug recommended for management of T2DM. Intolerable GI side effects of metformin leads to its discontinuation in 15-20% of patients leading to miss out of its multiple benefits. Imeglimin shares the insulin sensitizing MOA similar to metformin with and additional effect on insulin secretion without untoward side effects of metformin. Objective of this study was to observe efficacy and safety of Imeglimin in metformin intolerant participants.
Methods: Fifty-three subjects above their glycemic targets, on OHAs without metformin due to its intolerance were enrolled for this study. It was a prospective observational study. Imeglimin in a dose of 1 gm BD/day started in all participants for the 24 weeks without changing the existing regimen. HbA1c & weight was observed before and after the completion of study duration. Participants were asked to visit every week during observation period and sos if any side effects appeared.
Results: All participants completed the observation period. Male: female = 1:0.7, Average age was 46.7±7 years, Duration of diabetes was 4.1±3.1 years. Average HbA1c at start was 8.3±0.5 whereas after 24 weeks was 7.3±0.5 (The t-value is 9.95663. The p-value is &lt; .00001. The result is significant at p &lt; .05.). Average weight at start was 69±12.4 Kg whereas at completion was 69.5±12.5 Kg (The t-value is -0.21796. The p-value is .413944. The result is not significant at p &lt; .05). Three out of 7 whereas 1 out of 10 subjects with BMI above and less than 28 respectively, observed weight reduction of &gt;10% (The chi-square statistic is 1.4852. The p-value is .222969. The result is not significant at p &lt; .05.) Side effects observed were: withdrawn Imeglimin 1 (1.8%), Bloating: 5, increased Stool frequency: 3, Burning abdomen: 1.
Conclusion: Imeglimin show better GI tolerability as compared to metformin and significant Hba1c reduction with no effects on weight.

Disclosure
P.K. Agrawal: None. A. Gautam: None. N. Pursnani: None. A. Yadav: None.
895-P: Testosterone Replacement Therapy in Men with Hypogonadism and Type 2 Diabetes—ABCD Worldwide Audit
Authors: JONES THOMAS H. , HAIDER AHMAD , SULTAN HAIDER KARIM , CULL MELISSA L. , RYDER ROBERT E. 
Published: June 2024

Symptomatic testosterone deficiency is common affecting 40% of men with type 2 diabetes (T2D).1 Testosterone replacement therapy (TRT) has been shown to have benefits on reducing insulin resistance, improving glycemic control and relieving symptoms of hypogonadism.2,3,4 We present early data analysis from the Association of British Clinical Diabetologists (ABCD) Worldwide audit of Testosterone in men with T2D. The audit has already recruited 460 patients from 40 centres from 10 countries. Mean age 70.7&lt;u&gt;+&lt;/u&gt;9.35 years, mean total testosterone 9.22&lt;u&gt;+&lt;/u&gt;1.74nmol/l. TRT included parenteral lon-acting depot testosterone undeconoate and daily applied testosterone gels. All analysis by paired t-tests of parameters. HbA1c before and after TRT (1) 6 months 70.51 to 64.96 (n=163); (2) 12 months 70.82 to 61.06 (n=145) (3) 3 years 70.99 to 51.7 (n=125). Weight (kg) baseline 112.66kg at 3 years 107.15kg (p=0.61), Waist Circumference baseline 116.08cm to 115.12cm at 3 years (p=0.43). The Aging Male Symptom (AMS) Score is a marker of symptoms and quality of life. AMS score at baseline 40.83 after 12 months 21.93 (n=196) p&lt;0.001. Early analysis has provided evidence that TRT for men with T2D is associated with a progressive reduction in HbA1c over 3 years. No significant reduction of weight or waist circumference was identified. Importantly patients had a very significant improvement in quality of life and symptoms of testosterone deficiency. No adverse cardiovascular events were reported in patients in the audit up to 3 years TRT. Evidence from this ongoing audit that men who have symptoms of testosterone deficiency should have a fasting testosterone checked and if they fulfil the guideline criteria that consideration to be offered a trial of TRT. 1Kapoor D et al. Diabetes Care 2007:30;911-17, 2Kapoor et al. Eur J Endocrinol 2006:154;899-906, 3Jones TH et al. Diabetes Care 2011:34;828-37, 4Dhindsa S. et al. Diabetes Care 2016:39;82-91

Disclosure
T.H. Jones: None. A. Haider: Research Support; Bayer Inc., Grünenthal. K. Haider: Research Support; Bayer Inc., Grünenthal. M.L. Cull: None. R.E. Ryder: Speaker's Bureau; Abbott, Besins Healtcare, BioQuest, GI Dynamics. Consultant; GI Dynamics. Other Relationship; Novo Nordisk.

Funding
Association of British Clinical Diabetologists (ABCD)
896-P: Duodenal Mucosal Recellularization via Pulsed Electric Field–Induced Electroporation (ReCET) in Type 2 Diabetes—First-in-Human Experience
Authors: O'NEAL DAVID N. , SARTORETTO ADRIAN , EKINCI ELIF I. , MANOS GEORGINA , HOLT BRONTE , CAMERON GEORGINA , CHANDRAN SUJIEVVAN , VAUGHAN RHYS , ABU DAYYEH BARHAM K. 
Published: June 2024

Background: ReCET utilizing an endoscope administered non-thermal pulsed electric field to stimulate duodenal cellular regeneration may correct abnormal duodenal signaling in type 2 diabetes (T2D). We report updated results from a feasibility study of ReCET therapy in T2D.
Method: This multicenter, open-label, treatment-only study recruited 18-70 yr old; T2D ≤10 years; HbA1c 7.5%-11.0%; BMI 24 - 40 kg/m2; C-peptide ≥ 333 pmol/l; and on 1-4 non-insulin glucose-lowering medications (GLMs) which were unchanged post-procedure. Primary endpoint: Device/procedure-related serious adverse events (SAEs). Secondary endpoints: Changes in metabolic parameters at 24W.
Results: Participants received single energy application (Single Tx, n=12), double energy application (Double Tx, n=18), or the Gen 2 catheter (Gen 2, n=21)- (Figure 1). Procedure success was 100% with no related SAEs. Common AEs were sore throat (25/51) and transient diarrhea (11/51), and mostly (76%) mild. Glycemia improved post procedure with trends suggesting an energy-dose response (Figure 1). Mean (SD) HbA1c at 24 wks vs baseline was 7.2 (1.2%) vs. 8.8 (0.9)% (p&lt;0.01) in the Gen 2 group. Gen 2 group follow up is ongoing. Durability of glycemic improvement was observed in Double Tx group at 48 wks.
Conclusions: ReCET therapy is feasible and safe. Glycemic observations support further research.

Disclosure
D.N. O'Neal: None. A. Sartoretto: Research Support; Endogenex, Erbe Electromedizin GmbH. Advisory Panel; Bariatek. Consultant; Boston Scientific Corporation, Intuitive Surgical. E.I. Ekinci: Advisory Panel; Lilly Diabetes. Research Support; Novo Nordisk, Boehringer-Ingelheim, Eli Lilly and Company. Board Member; Eli Lilly and Company. Advisory Panel; Abbott. Research Support; Endogenex, Versanis, AstraZeneca. G. Manos: None. B. Holt: None. G. Cameron: None. S. Chandran: None. R. Vaughan: None. B.K. Abu Dayyeh: Research Support; USGI Medical, Apollo Endosurgery. Consultant; Boston Scientific Corporation, Medtronic. Other Relationship; Endogenex. Research Support; ERBE.
90-OR: Neddylation Targets Cullin 3 to Regulate Adipocyte Differentiation
Authors: ZHOU HONGYI , CHEN WEIQIN 
Published: June 2024

Introduction & Objective: The ongoing obesity epidemic has raised awareness of the complex physiology of adipose tissue (AT). Abnormal adipocyte differentiation will result in the development of systemic metabolic disorders such as insulin resistance and diabetes. The conjugation of NEDD8 (neural precursor cell expressed, developmentally downregulated 8) to target protein, termed neddylation, has been shown to mediate adipogenesis by targeting PPARγ. However, much remains unknown about its role in adipogenesis.
Methods: Adipocyte differentiation was studied in 3T3-L1 cells and human Stromal vascular cells with pharmacological inhibition and genetic deletion by CRISPR/Cas9 of neddylation enzymes and its targeted cullins. Adipogenic signaling was analyzed by Western Blot, RT-PCR, FACS, etc.
Results: We first reported that neddylation and its targets, the cullin (CUL) family members, are differentially regulated during mouse and human adipogenesis. Neddylation inhibition by MLN4924 blunts adipogenesis in both 3T3-L1 cells and human stromal vascular cells. CRISPR/Cas9-mediated NAE1 deletion, a subunit of the only NEDD8 E1 enzyme, suppresses neddylation and impairs adipogenesis. Further studies identified that neddylation inhibition does not alter cell cycle progression, as evidenced by unaltered mitotic cell expansion. Instead, it impairs CREB-C/EBPβ-PPARγ signaling essential for adipogenesis. Furthermore, among different neddylation-targeted CULs, deletion of CUL3, but not CUL1, CUL2, and CUL4A, largely recapitulates neddylation deficiency-induced adipogenesis defects.
Conclusion: Our data establishes an indispensable role for neddylation and its target CUL3 in adipogenesis and suggests they can be important therapeutic targets for obesity.&lt;u&gt;&lt;/u&gt;

Disclosure
H. Zhou: None. W. Chen: None.

Funding
National Institutes of Health (1R56 DK135657 and 2R01HL132182)
900-P: A Real-World, Multicentre, Retrospective, Observational Study to Evaluate the Effectiveness and Safety of Lobeglitazone in Type 2 Diabetes Mellitus Patients in India (LODIAB INDIA)
Authors: BARKATE HANMANT V. , CHITNIS KRUTTIKA R. , PETARE ANUP U. , CHOUDHARI SANJAY Y. , BHUSHAN SUMIT , PATIL SAIPRASAD 
Published: June 2024

Background: Lobeglitazone, a novel TZD was recently approved in India for T2DM, has limited real-world data. This study assessed the effectiveness and safety of Lobeglitazone 0.5 mg once daily in real-world settings.
Methods: Data was captured from the medical records of patients after obtaining independent ethics committee approval from 16 different sites across India. The primary outcome was % change in HbA1c at week 12. Secondary outcomes were changes in the fasting blood sugar (FBS), post-prandial blood sugar (PPBS), lipid, liver and renal parameters and treatment emergent adverse effects at week 12. Statistical analysis was performed using paired t-test.
Results: Records of N=544 patients (60.4% males and 39.6% females), with a mean age of 52.6 ± 11.8 years were analysed. Baseline mean HbA1c reduced from 8.82 ± 1.57% to 7.62 ± 1.3% (mean reduction: 1.2%, p-value&lt;0.0001; Figure 1). Proportion of patients achieving HbA1c &lt;7% was 31.6% at week12. Changes in glycemic, lipid, liver and renal parameters are depicted in Table 1. There were no significant changes in body weight (p=0.17). Increase and decrease in the body weight and pedal oedema were reported in 0.92%, 2.39% and 0.37% individuals respectively. There were no reports of hypoglycaemia or any cardiac events in the enrolled patients.
Conclusion: Lobeglitazone significantly improved glycemic parameters, Sr. creatinine, Sr. bilirubin and total cholesterol levels and was well tolerated in Indian Type 2 diabetes patients in the real world setting.
Figure 1: Graphical Representation of change in HbA1c% at week12Table 1: Changes in glycemic, lipid, liver and renal parameters from baseline to week12

Disclosure
H.V. Barkate: Employee; Glenmark Pharmaceuticals. K.R. Chitnis: None. A.U. Petare: Employee; Glenmark Pharmaceuticals. S.Y. Choudhari: Employee; Glenmark Pharmaceuticals, Sun Pharmaceutical Industries Ltd. S. Bhushan: None. S. Patil: Employee; Glenmark Pharmaceuticals.
904-P: Glycemic Improvement in Patients with Type 2 Diabetes under Treatment with a Fixed-Dose Combination Glimepiride/Vildagliptin/Metformin with Failure to Previous Dual Therapy
Authors: RIOS-BRITO KEVIN F. , RODRIGUEZ-ROCANDIO KARLA E. , SANDER-PADILLA JOSE G. , LUGO-SÁNCHEZ LAURA A. , ROMERO YULIA , ARGUEDAS MARÍA M. , MORA JULIO C. , RODRIGUEZ-VAZQUEZ ILEANA C. , FLORES-HUANOSTA DIANA , GONZALEZ-CANUDAS JORGE 
Published: June 2024

Introduction & Objective: Failure to type 2 diabetes (T2D) treatment leads to complications. Combination therapies with different mechanisms of action are often required to achieve glycemic goals. This study aimed to evaluate the efficacy and safety of glimepiride/vildagliptin/metformin in patients with T2D.
Methods: A multicenter, randomized, double-blind study was conducted. Patients over 18 years with previous dual therapy and inadequate glycemic control (glycated hemoglobin (HbA1c) ≥7.0% and ≤11.0%) were included. Participants were initially treated with glimepiride 1/vildagliptin 50/metformin 500 mg. At 45 days, HbA1c was evaluated, patients with efficacy (reduction of HbA1c ≥0.3%) continued with the same treatment, and those with no response were randomly assigned to (2/50/1000 mg) or (4/50/1000 mg). The primary endpoint was efficacy at 90 days.
Results: We enrolled 113 participants (mean age 53 years, HbA1c 9.5 ± 1.0%), three previous therapies were described: Biguanide/Sulfonylurea (62.8%), Biguanide/DPP-4 inhibitors (29.2%) and Biguanide/SGLT2 inhibitors (8.0%). At 45 days, 65.8% of patients showed a positive response, independently of their previous therapy, and 34.2% were escalated. %HbA1c differences were reported: Biguanide/Sulfonylurea (9.5 to 8.7, p=0.001), Biguanide/DPP-4 inhibitors (9.4 to 8.3, p=0.001), and Biguanide/SGLT2 inhibitors (9.3 to 8.6, p=0.040). Over 90 days of follow-up, 107 patients completed the study and 72 achieved a reduction of HbA1c ≥0.3% (63.7%). Three mild hypoglycemic events were reported with the starting dose.
Conclusion: Glimepiride/vildagliptin/metformin therapy improved glycemic control in patients with T2D and previous dual combination failure, this treatment was well tolerated with a low incidence of hypoglycemia.

Disclosure
K.F. Rios-Brito: Employee; Laboratorios Silanes S.A. de C.V. K.E. Rodriguez-Rocandio: Employee; Laboratorios Silanes S.A. de C.V. J.G. Sander-Padilla: Employee; Laboratorios Silanes. L.A. Lugo-Sánchez: Employee; Laboratorios Silanes S.A. de C.V. Y. Romero: Employee; Laboratorios Silanes. M.M. Arguedas: Employee; Laboratorios Silanes S.A. de C.V. J.C. Mora: Employee; Laboratorios Silanes. I.C. Rodriguez-Vazquez: Employee; Laboratorios Silanes S.A. de C.V. D. Flores-Huanosta: Employee; Laboratorios Silanes. J. Gonzalez-Canudas: Employee; Silanes SA CV.

Funding
Laboratorios Silanes S.A. de C.V.
92-OR: Defining Type 1 Diabetes Endtypes
Authors: BEDRAT AMINA , PANT TARUN , JIA SHUANG , ROETHLE MARK , TRUCHAN NATHAN A. , CHEN YI-GUANG , LIN CHIEN-WEI , HESSNER MARTIN 
Published: June 2024

To explore T1D heterogeneity, the existence of endotypes, and their possible differential responses to immunotherapy administered at clinical onset, we studied 566 TrialNet clinical trial participants (MMF-DZB, anti-CD20; GAD-alum; CTLA4-Ig; Canakinumab; ATG-GCSF). A bioassay, where participant serum is used to induce transcription in healthy mononuclear cells, and unsupervised cluster analyses were used to identify 2 major groups (Gp1 and Gp2).Proportional analyses of subjects &lt;18 years found Gp1 enriched with participants &lt;14 years old (p=0.03); further Gp1 placebo arm participants exhibited a more rapid C-peptide rate of decline (&lt;-0.15, p=0.02). Pathway analysis of transcriptomic data predicted inflammatory bias in Gp1, that was confirmed by detection of elevated plasma IFNγ, TNFα, and IL-6 levels (p&lt;0.01), and higher memory T-cell abundances. When assessing response to therapy, Gp1 anti-CD20-treated participants exhibited a higher mean C-peptide compared to placebos at 6, 12 and 24 months post-onset (meta-p=0.002 vs 0.27 in Gp2) and a greater delay in the post-onset decline of baseline stimulated C-peptide (11.2 vs 5.4 months). In contrast, Gp2 CTLA4-Ig-treated participants exhibited a higher mean C-peptide compared to placebos at 6, 12, 18 and 24 months (meta p=2e-4 vs. 0.24 in Gp1) and a greater delay in the decline of baseline stimulated C-peptide (8.7 vs 5.8 months). Both Gp1 and Gp2 benefited from ATG treatment, respectively showing 9.5 and 6.7 month delays in the decline in baseline stimulated C-peptide compared to their corresponding placebos. Weighted correlation network analyses of transcriptomic data suggested that varying degrees of immunomodulation occurred in all 6 trials, including those not showing overall efficacy. In line with that observation, Gp2 canakinumab-treated participants showed a 3.4-month delay in the decline in baseline stimulated C-peptide compared to placebos. These data support the existence of two T1D endotypes that exhibit distinct immune phenotypes and therapeutic responsiveness.

Disclosure
A. Bedrat: None. T. Pant: None. S. Jia: None. M. Roethle: None. N.A. Truchan: None. Y. Chen: None. C. Lin: None. M. Hessner: None.

Funding
R01DK121528
927-P: Sodium–Glucose Cotransporter 2 Inhibitors Use during Ramadan in People with Type 1 Diabetes—Observational Study
Authors: ALOZAIRI EBAA S. , IRSHAD MOHAMMAD , SOJAN LITTY G. , ALROUDHAN DHERAR , TAGHADOM ETAB , ALKANDARI JUMANA 
Published: June 2024

Introduction & Objective: Sodium-glucose cotransporter-2 (SGLT2) inhibitors represent a novel class of anti-hyperglycemic agents with added benefit of renal protection. Their use in type 1 diabetes is limited. During Ramadan Muslims fast from sunset to sunrise, abstaining from both food and drink which increase the potential risk of dehydration and adverse effects. This study aimed to compare glycemic metrics and adverse events in fasting and non-fasting people with Type 1 Diabetes (T1D) using SGLT2 inhibitors during Ramadan.
Methods: In this prospective observational study, twenty-five people with T1D (mean age± SD: 40.4± 10.4 years, HbA1c: 7.8%± 1.2%) were divided into fasted (n=12) and non-fasted (n=13) groups. Participants received a stable dose of SGLT2 inhibitors before fasting and using continuous glucose monitoring (CGM) device. Outcomes measured differences in percentage time spent in the target range (3.9-10 mmol/L), hypoglycemic range (&lt;3.9 mmol/L), hyperglycemic range (&gt;10 mmol/L), glucose variability (CV%), and diabetes ketoacidosis between groups. All people underwent structured education for the safe use of SGTL2 inhibitors.
Results: The mean fasting duration was 26.2± 3.5 days (range: 18-29 days). No significant differences were observed in the target range (-8.0± 11.2% vs. -0.6± 10.3%), hyperglycemic range (8.2± 11.5% vs. 0.3± 10.7%), hypoglycemic range (-0.2 ±2.7% vs. 0.3± 10.7%) and glycemic variability (1.0± 2.6% vs. -0.5± 5.4%) between fasting and non-fasting groups using SGLT2 inhibitors. No severe hypoglycemia, diabetic ketoacidosis (DKA), or hospitalizations occurred in either group during the fasting period.
Conclusions: The use of SGLT2 inhibitors in people with T1D during Ramadan fasting appears safe and well-tolerated, with no reported adverse events for people undergoing structured education. However, further clinical trials are necessary to validate these findings.

Disclosure
E.S. Alozairi: None. M. Irshad: None. L.G. Sojan: None. D. Alroudhan: None. E. Taghadom: None. J. AlKandari: None.

Funding
Kuwait Foundation for the Advancement of Sciences (KFAS), Kuwait
937-P: Efficacy and Safety of SGLT2i vs. Other Oral Antidiabetic Drugs as Dual Therapy Add-On to Metformin in Type 2 Diabetes—A Systematic Review and Meta-analysis
Authors: MA YUHANG , LIN YI , DING XIAOYING , PENG YONGDE 
Published: June 2024

Introduction & Objective: The combination of metformin (met) with other oral antidiabetic drugs (OADs) like sodium-glucose cotransporter-2 inhibitors (SGLT-2i) is recommended by international guidelines for type 2 diabetes mellitus treatment. This systematic literature review (SLR) and meta-analysis (MA) compared the efficacy and safety specifically of dual therapy with SGLT-2i versus other OADs as add-on to met.
Methods: An update to a 2016 SLR was conducted to identify randomized controlled trials (RCTs) comparing dual therapies of OADs + met. Searches of MEDLINE, Embase, the Cochrane Library, recent congresses and SLR bibliographies were conducted in May 2023. RCTs were assessed using the Cochrane Risk of Bias tool. MAs employing random effect models compared change in haemoglobin A1c (HbA1c) and adverse events with SGLT-2i versus other OADs as add-on to met at Week 52.
Results: A total of 23 RCTs comprising of 11,911 patients on oral met-containing dual therapies (SGLT-2is, dipeptidyl peptidase-4 inhibitors, oral glucagon-like peptide-1 receptor agonists and sulfonylureas) were included. The mean difference (MD) in change from baseline of HbA1c with SGLT-2i + met versus other OADs + met was comparable (MD 0.01, 95% confidence interval [CI] -0.16-0.18). In terms of safety, SGLT-2i + met had a significantly lower risk of hypoglycaemia (risk ratio [RR] 0.27, 95% CI 0.09-0.84) and lower risk of myocardial infarction (MI) (RR 0.58, 95% CI 0.16-2.07) than other OADs + met. However, risk of urinary tract infection (UTI) was higher (RR 1.22, 95% CI 0.94-1.58).
Conclusion: Compared with other OADs + met dual therapies, SGLT-2i + met exhibited noninferior efficacy and significantly reduced risk of hypoglycaemia while risks of MI and UTI were not significantly different. Results from this study reinforce the recommendation of dual therapy in international guidelines, depending on patients’ treatment goals and risk profiles.

Disclosure
Y. Ma: None. Y. Lin: None. X. Ding: None. Y. Peng: None.